A phase II trial of dostarlimab and niraparib combination therapy in patients with stage III-IV recurrent or refractory penile cancer. Association of baseline and on-treatment ctDNA fraction with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback